CRIS curis.com Yalpi foyda bo'yicha sotuv rentabelligi

CRIS (Curis, Inc.) - kompaniyaning tovar belgisi

Curis, Inc. onkologiya bozorining kattaroq ulushini egallash uchun emavusertib qo'llanilishini kengaytirishni maqsad qilgan. Ushbu ambitsiyalar maqsadli terapiyalarni ishlab chiqishda Roche va Genentech bilan hamkorlik orqali qo'llab-quvvatlanmoqda. Valo profit marginini tahlil qilib, GURU.Markets dan olingan ushbu grafik qiymat 94.60 darajasida saqlanayotganini ko'rsatmoqda. Biroq, yuqori kapital xarajatlari va tartibga soluvchi murakkabliklar investorlar uchun aksiyalar ulushining kamayishi xavflarini yuzaga keltirmoqda.

CRIS (Curis, Inc.) Yalpi marja tarixi 04.07.2022dan 20.11.2026gacha

Curis Corp (CRIS) moliyaviy va bozor koʻrsatkichlari kesimi

- joriy kotirovkalar va o'rtacha qiymat prognozi:
Kompaniyaning jamlanma tahlili:CRIS - Curis, Inc.
Curis Inc. brendining mahsuloti

Uzoq muddatli risklarni boshqarish uchun, bevosita ishlab chiqarish xarajatlari chegirib tashlanganidan keyin qolgan daromad qismini o'lchovchi yalpi foyda dinamikasini kuzatish juda muhimdir. Curis, Inc. (CRIS) kompaniyasining yalpi foydaning daromadga nisbati tahlili, maqsadli dori vositalarining patent himoyasi tufayli yuqori ustamalarga ega bo'lish imkoniyatini tasdiqlaydi, bu esa kompaniyaga saraton terapiyasi sohasida barqaror raqobatbardoshlik afzalligi va fundamental biznes quvvatini taqdim etadi.

Toʻgʻridan-toʻgʻri raqobatchilar

Yalpi foyda marjasi BeiGene Ltd. (ONC)|Yalpi foyda bo'yicha rentabellik HALO|Yalpi rentabellik RVMD|Yalpi foyda bo'yicha rentabellik AAPG (Ascentage)|Yalpi foyda bo'yicha rentabellik cgoncology.com CGON|UroGen Pharma - Yalpi foyda bo'yicha rentabellik|Yalpi foyda normasi BCAX|PSNL - Yalpi rentabellik|Yalpi foyda bo'yicha sotuv rentabelligi Erasca Oncology ERAS|delcath.com (DCTH) - Yalpi rentabellik|Y-mAbs Therapeutics - Yalpi foyda normasi|AURA (Aura Biosciences Inc) - Yalpi marja|Yalpi foyda marjasi candeltx.com CADL|Yalpi marja ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Yalpi foyda normasi|Yalpi rentabellik Actuate Therapeutics, Inc. ACTU|citiusonc.com - Yalpi rentabellik|TuHURA Biosciences Inc. - Yalpi marja|TARA - Yalpi marja|FATE (Fate Therapeutics) - Yalpi foyda bo'yicha rentabellik|Yalpi foyda bo'yicha rentabellik Aadi Bioscience, Inc.|Yalpi foyda bo'yicha rentabellik TCRX|Yalpi rentabellik CSBR|Yalpi marja XBIT|Yalpi foyda bo'yicha sotuv rentabelligi CEL-SCI Corp.|Yalpi rentabellik ostherapies.com OSTX|RADX: Sotuvning yalpi rentabelligi|ARTV: Yalpi foyda bo'yicha rentabellik|ANL (Adlai Nortye) - Sotuvning yalpi rentabelligi|Veru (VERU) - Yalpi rentabellik|Yalpi foyda bo'yicha rentabellik Tempest Therapeutics Inc|Yalpi rentabellik Xilio Therapeutics|Sotuvning yalpi rentabelligi RENB (Renovaro Inc.)|Yalpi rentabellik Mural Oncology PLC (MURA)|Yalpi marja Kairos Pharma (KAPA)|Yalpi rentabellik onkuretherapeutics.com OKUR|GDTC: Sotuvning yalpi rentabelligi|Apollomics - Yalpi marja|Tharimmune Corp (THAR) - Yalpi foyda bo'yicha rentabellik|ADVB: Yalpi marja|Yalpi foyda bo'yicha rentabellik Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Yalpi marja|Sotuvning yalpi rentabelligi SBFM (Sunshine Biopharma)|Yalpi rentabellik Xenetic Bio (XBIO)|Yalpi rentabellik SLRX (Salarius Pharma)|Kitov Pharma - Yalpi foyda bo'yicha rentabellik|American Oncology Network (AONC) - Yalpi foyda marjasi|BeiGene - Yalpi marja|Checkpoint Therapeutics, Inc. (CKPT) - Yalpi foyda bo'yicha rentabellik|ELEV (Elevation Oncology, Inc.) - Yalpi foyda bo'yicha rentabellik|iCAD Inc. - Yalpi foyda normasi|Yalpi foyda bo'yicha rentabellik IKNA|Yalpi marja notablelabs.com|Yalpi foyda bo'yicha rentabellik VIRX (Viracta Therapeutics Inc.)|MOR - Yalpi foyda marjasi|Yalpi rentabellik NAYA Biosciences NAYA|AAPGV - Yalpi foyda bo'yicha rentabellik